NPY and Prader-Willi syndrome: Diazoxide, an ATP-sensitive K+ channel (K-ATP) agonist, has been reported to have the therapeutic effect on children and adults with PWS through insulin secretion from pancreatic β-cells, modulation of hypothalamic NPY, the most potent endogenous neuropeptide, and activation of K-ATP channels in adipocytes [56].